RVMD Stock Forecast: Revolution Medicines, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$161
+0.98% on the day

The 24 Wall Street analysts covering Revolution Medicines, Inc. hold a median 12-month price target of $272 — +68.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$34.5B
Ticker Nerd rank
56/ 100
Median analyst target
$272
Analysts covering
24
Revenue$0.0
Operating income−$505.1M
Net income−$644.4M
Free cash flow−$745.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.6%
1M
−18.1%
YTD
+102.1%
1Y
+130.4%
From 52W high
−27.2%
From 52W low
+130.4%
$70
$221
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Revolution Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
56/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
91
Revisions
89
Volatility
66
Quality
49
Accruals
42
Growth
24
Issuance
8

Momentum (97): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RVMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RVMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$100$200$300$400Jan 26Apr 26Jul 26Oct 26RVMDHigh $350Median $272Low $179

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
23
Buy
1
Hold
0
Sell
$179
Low
$272
Median
$350
High

The green dot is the last close — the median target sits +68.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 12 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
17 Nov 2026HC Wainwright & Co.ReiteratesBuy$350
13 Nov 2026Morgan StanleyMaintainsOverweight$272 → $247
6 Nov 2026HC Wainwright & Co.MaintainsBuy$280 → $350
5 Nov 2026Evercore ISI GroupMaintainsOutperform$320 → $340
5 Nov 2026GuggenheimMaintainsBuy$275 → $298
5 Nov 2026Piper SandlerMaintainsOverweight$210 → $222
5 Nov 2026RBC CapitalMaintainsOutperform$260 → $321
5 Nov 2026TD CowenMaintainsBuy$250 → $270
5 Nov 2026Truist SecuritiesReiteratesBuy$241 → $261
21 Oct 2026TD CowenReiteratesBuy$250
19 Oct 2026Truist SecuritiesMaintainsBuy$240 → $241
16 Oct 2026William BlairInitiatesOutperform—
15 Oct 2026NeedhamReiteratesBuy$275
14 Oct 2026RBC CapitalMaintainsOutperform$259 → $260
8 Oct 2026RBC CapitalMaintainsOutperform$251 → $259
7 Oct 2026Truist SecuritiesMaintainsBuy$239 → $240
28 Sept 2026Brookline CapitalInitiatesBuy$318
24 Sept 2026Goldman SachsReinstatesBuy$267
21 Sept 2026B of A SecuritiesMaintainsBuy$225 → $265
10 Sept 2026Morgan StanleyInitiatesOverweight$255

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RVMD.

Market Radar

This page is one stock. Monday covers all of them.

RVMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RVMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Revolution Medicines, Inc. returned +130.4% against +6.9% for the S&P 500, dividends included.

RVMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26RVMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RVMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
14
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
183.4×

Cheaper than 2% of US stocks

Price / book
15.1×

Cheaper than 5% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−93.6%

Higher than 14% of US stocks

Return on assets
−32.1%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Revolution Medicines, Inc. has a market value of $34.5B and an enterprise value of $32.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$1.8B.

  • Diluted earnings per share, trailing twelve months: −$8.82.

  • Free cash flow in the twelve months to 30 June 2026: −$1.6B.

  • Shares outstanding: 214.2M.

  • Revolution Medicines, Inc. employs 883 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

RVMD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RVMDRevolution Medicines, Inc.$34.5B56
INSMInsmed, Inc.$30.9B76
RPRXRoyalty Pharma Plc$39.4B97
ROIVRoivant Sciences Ltd.$27.7B83
INCYIncyte Corp.$22.9B89
ALNYAlnylam Pharmaceuticals, Inc.$19.3B58
ASNDAscendis Pharma A/S$16.6B93

Take a look at RVMD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Revolution Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RVMD

What is the RVMD stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Revolution Medicines, Inc. have a median 12-month price target of $272, with estimates ranging from $179 to $350. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RVMD stock a buy right now?

Of the 24 analysts covering Revolution Medicines, Inc., 23 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revolution Medicines, Inc. 56 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RVMD?

As at 21 Nov 2026, Revolution Medicines, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will RVMD stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +68.6% from the last close, and Ticker Nerd's factor model ranks Revolution Medicines, Inc. 56 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RVMD stock forecast for 2030?

No analyst covering Revolution Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $179 to $350 over the next 12 months.

How has RVMD stock performed over the past year?

Revolution Medicines, Inc. returned +130.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Revolution Medicines, Inc. do?

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors.

Company

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.

CEO Dr. Mark A. Goldsmith M.D., Ph.D. · 883 employees · United States · https://www.revmed.com